Clinical trials: IgAN - IgA Nephropathy
IgA Nephropathy (IgAN)
Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients
This study at UCLA Center for Health Sciences is testing whether the Autoimmune Protocol (AIP) diet can lower protein levels in the urine of people with IgA Nephropathy (IgAN), a common kidney disease that can lead to kidney…
- Trial name
- NCT07022574
- Testing
- Low inflammation diet intervention
- Where
- United States
- Sponsor
- University of California, Los Angeles
Cutaneous Vasculitis
IgA-positive Versus IgA-negative Immune Complex Vasculitis
Cutaneous vasculitis due to vascular deposition of large circulating immune complexes is a disease frequently seen by general practitioners and dermatologists.
- Trial name
- NCT01815190
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
IgA Nephropathy
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
This is a Phase II, open-label study designed to To evaluate the safety and efficacy of NM8074 in reducing proteinuria relative to baseline in IgAN patients after 99 days of treatment.
- Trial name
- NCT06454110
- Testing
- NM8074
- Volunteers
- 10 people
- Sponsor
- NovelMed Therapeutics
ANCA Associated Vasculitis, Extramembranous Glomerulopathy
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.
- Conditions
- ANCA Associated Vasculitis, Extramembranous Glomerulopathy, Nephrotic Syndrome, Minimal Change, Interstitial Nephritis
- Trial name
- PROTECT-Fi (NCT07010250)
- Where
- France
- Volunteers
- 146 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glomerulonephritis, IGA
Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy
Along structural IgA abnormalities, hyperproduction of IgA is thought to play a role in the pathogenesis of primary IgA nephropathy.
- Trial name
- NCT00521508
- Testing
- gene transcription and cytometry
- Where
- France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
IgA Nephropathy
A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.
- Trial name
- NCT05824390
- Testing
- rituximab group
- Where
- China
- Volunteers
- 116 people
- Sponsor
- XIEJINGYUAN
Primary IgA Nephropathy
Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy
The study is being conducted to evaluate the efficacy, and safety of SHR - 2010 injection in patients with primary IgA nephropathy.
- Trial name
- NCT05847920
- Testing
- SHR-2010 Injection
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
IgA Nephropathy (IgAN)
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.
- Trial name
- NCT06676579
- Testing
- Avacopan, Prednisone, Methylprednisolone (drug)
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects. VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL.
- Conditions
- Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
- Trial name
- NCT03719443
- Testing
- VIS649
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary IgA Nephropathy
A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy
To evaluate the safety and efficacy of Tai Ai(Recombinant Human B Lymphocyte Stimulator Receptor-Antibody Fusion Protein for Injection) in the treatment of IgA nephropathy.
- Trial name
- NCT04291781
- Testing
- RC18 160mg, RC18 240mg
- Where
- China
- Volunteers
- 44 people
- Sponsor
- RemeGen Co., Ltd.
IgA Nephropathy
Study of ARO-CFB in Adult Healthy Volunteers
The purpose of AROCFB-1001 is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ARO-CFB Injection in adult healthy volunteers (HVs). HVs will receive either one or two doses of ARO-CFB or placebo.
- Trial name
- NCT06209177
- Testing
- ARO-CFB
- Where
- New Zealand
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Diabetic Kidney Disease, IgA Nephropathy
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of SC0062 capsule in patients with chronic kidney disease (diabetic kidney disease and IgA nephropathy)with albuminuria compared to…
- Trial name
- NCT05687890
- Testing
- SC0062 low dose, SC0062 medium dose, SC0062 high dose
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
IgA Nephropathy
A Clinical Research on the Use of Fecal Bacteria Transplantation for Treatment of IgA Nephropathy
The role and related mechanisms of gut microecology in the development and progression of IgA nephropathy were investigated by treating IgA nephropathy subjects with oral probiotic capsules (FMT) combined with metagenomic…
- Trial name
- NCT05182775
- Testing
- Fecal bacteria transplantation
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Shanxi Provincial People's Hospital
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy…
- Trial name
- NCT06004947
- Testing
- CCX168, Midazolam, Celecoxib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
IgA Nephropathy
A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients
This study is to evaluate efficacy and safety of tacrolimus in the patients with non-nephrotic albuminuric, normotensive IgA nephropathy after 16 week treatment with tacrolimus (Prograf) or placebo.
- Trial name
- NCT01224028
- Testing
- Tacrolimus
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Astellas Pharma Inc
IGA Nephropathy, Proteinuria
Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy
The purpose of this study is to evaluate the safety of several dose levels of CCL2-LPM in patients with IgA Nephropathy who have high levels of protein in the urine.
- Trial name
- NCT00856674
- Testing
- OPL-CCL2-LPM
- Where
- 3 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Osprey Pharmaceuticals USA, Inc.
IgA Nephropathy
Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers
This study will help to show the efficacy of vitamin D and address the optimal strategy to minimize renal injury in IgAN patients.
- Trial name
- NCT01237028
- Testing
- Calcitriol
- Where
- 7 sites in South Korea
- Volunteers
- 168 people
- Sponsor
- Yonsei University
Primary IgA Nephropathy
A Trial of HRS-5965 Tablets in Primary IgA Nephropathy
The study is being conducted to evaluate the efficacy, and safety of HRS-5965 tablets for primary IgA nephropathy. To explore the effective dosage of HRS-5965 tablets for primary IgA nephropathy.
- Trial name
- NCT06137768
- Testing
- HRS-5965
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Primary IgA Nephropathy
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials.
- Trial name
- NCT04557462
- Testing
- LNP023
- Where
- 161 sites in United States, Argentina and 34 more
- Volunteers
- 540 people
- Sponsor
- Novartis Pharmaceuticals
Proteinuria
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
- Trial name
- NCT05314231
- Testing
- ALXN1720
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.